| 1 |
James JK, Palmer SM, Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections[J]. Antimicrob Agents Chemother, 1996, 40(3):696-700.
|
| 2 |
Roberts JA, Lipman J, Blot S, et al. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients？[J]. Curr Opin Crit Care, 2008, 14(4):390-396.
|
| 3 |
Knudsen JD, Fuursted K, Raber S, et al. Pharmacodynamics of Glycopeptides in the Mouse, Peritonitis Model of Streptococcus pneumoniae, or Staphylococcus aureus Infection[J]. Antimicrob Agents Chemother, 2000, 44(5):1247-1254.
|
| 4 |
Ampe E, Delaere B, Hecq JD, et al. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.[J]. Int J Antimicrob Agents, 2013, 41(5):439-446.
|
| 5 |
Saugel B, Gramm C, Wagner JY, et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: An observational study in intensive care unit patients [J]. J Crit Care, 2014, 29(3):351-355.
|
| 6 |
Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients[J]. Antimicrob Agents Chemother, 2009, 53(5):1863-1867.
|
| 7 |
Buyle FM, Decruyenaere J, Waele JD, et al. A survey of beta-lactam antibiotics and vancomycin dosing strategies in intensive care units and general wards in Belgian hospitals[J]. Eur J Clin Microbiol Infect Dis, 2013, 32(6):763-768.
|
| 8 |
Hong LT, Goolsby TA, Sherman DS, et al. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients [J]. J Crit Care, 2015, 30(5):1153.e1-1153.e6.
|
| 9 |
Waineo MF, Kuhn TC, Brown DL. The pharmacokinetic/pharmacodynamics rationale for administering vancomycin via continuous infusion.[J]. J Clin Pharm Ther, 2015, 40(3):259-265.
|
| 10 |
Davis SL, Scheetz MH, Bosso JA, et al. Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U．S. hospitals[J]. Pharmacotherapy, 2013, 33(12):1256-1263.
|
| 11 |
Morrison AP, Melanson SE, Carty MG, et al. What proportion of vancomycin trough levels are drawn too early？：frequency and impact on clinical actions.[J]. Am J Clin Pathol, 2012, 137(3):472-478.
|
| 12 |
Payne CJ, Thomson AH, Stearns AT, et al. Pharmacokinetics and tissue penetration of vancomycin continuous infusion as prophylaxis for vascular surgery[J]. J Antimicrob Chemother, 2011, 66(11):2624-2627.
|
| 13 |
Verrall A, Llorin R, Lye D, et al. Efficacy of Continuous Infusion Vancomycinfor the outpatient treatment of Methicillin-ResistantStaphylococcus aureus Infections[C]// Infectious Diseases Society of America. 2011.
|
| 14 |
Wysocki M, Delatour F, Faurisson F, et al. Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study[J]. Antimicrob Agents Chemother, 2001, 45(9):2460-2167.
|
| 15 |
Dimondi VP, Rafferty K. Review of continuous-infusion vancomycin[J]. Ann Pharmacother, 2013, 47(2):219-227.
|
| 16 |
Hao JJ, Chen H, Zhou JX. Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis[J]. Int J Antimicrob Agents, 2016, 47(1):28-35.
|
| 17 |
Jeurissen A, Sluyts I, Rutsaert R. A higher dose of vancomycin in continuous infusion is needed in critically ill patients[J]. Int J Antimicrob Agents, 2011, 37(1):75-77.
|
| 18 |
Ingram P, Lye DC, Tambyah PA, et al. Risk Factors for Nephrotoxicity associated with Continuous Vancomycin Infusion in Outpatient Parenteral Antibiotic Therapy[J]. J Antimicrob Chemother, 2008, 62(1):168-171.
|
| 19 |
Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis.[J]. J Antimicrob Chemother, 2012, 67(1):17-24.
|
| 20 |
Saugel B, Nowack MC, Hapfelmeier A, et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients [J]. J Crit Care, 2012, 28(1):9-13.
|
| 21 |
薛敬一，徐晓涵，陈恳，等. 万古霉素持续输注与间断输注的系统评价与Meta分析[J]. 中国临床药理学杂志，2015, (13):1348-1352.
|
| 22 |
Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides.[J]. Critical Care Medicine, 2005, 33(9):1983-1987.
|
| 23 |
Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists[J]. Pharmacotherapy, 2009, 29(29):1275-1279.
|
| 24 |
Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia[J]. J Clin Microbiol, 2004, 42(6):2398-2402.
|
| 25 |
Neely MN, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for optimal dosing？[J]. Antimicrob Agents Chemother, 2014, 58(1):309-316.
|
| 26 |
Martinez MN, Papich MG, Drusano GL. Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic Target[J]. Antimicrob Agents Chemother, 2012, 56(6):2795-2805.
|
| 27 |
De Waele JJ, Lipman J, Carlier M, et al. Subtleties in practical application of prolonged infusion of β-lactam antibiotics[J]. Int J Antimicrob Agents, 2015, 45(5):461-463.
|
| 28 |
Baptista JP, Sousa E, Martins PJ, et al. Augmented renal clearance in septic patients and implications for vancomycin optimisation[J]. Int J Antimicrob Agents, 2012, 39(5):420-423.
|
| 29 |
Roberts JA, Taccone FS, Udy AA, et al. Vancomycin Dosing in Critically Ⅲ Patients: Robust Methods for Improved Continuous-Infusion Regimens[J]. Antimicrob Agents Chemother, 2011, 55(6):2704-2709.
|
| 30 |
Tafelski S, Nachtigall I, Troeger U, et al. Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: Continuous versus intermittent application[J]. J Infect Public Health, 2015, 8(4):355-363.
|
| 31 |
Jeurissen A, Sluyts I, Rutsaert R. A higher dose of vancomycin in continuous infusion is needed in critically ill patients[J]. Int J Antimicrob Agents, 2011, 37(1):75-77.
|